According to BTIG Research, value stocks are closing at a 40-year low relative to growth. The primary reason is that ...

Fintel reports that on January 8, 2025, BTIG downgraded their outlook for Inari Medical (NasdaqGS:NARI) from Buy to Neutral.

In a report released today, Ryan Zimmerman from BTIG reiterated a Buy rating on Globus Medical (GMED – Research Report), with a price target of ...

“In 2025, the energy sector will be less about barrels of oil and more about...billions of cubic feet of natural gas demand in 2025 and beyond as the technology sector intersects with the energy ...

BTIG Research has recently reduced Fiverr International Ltd (FVRR) stock to Neutral rating, as announced on November 4, 2024, according to Finviz. Earlier, on July 2, 2024, UBS had reduced the stock ...

BTIG analyst Ryan Zimmerman maintained a Buy rating on Stryker (SYK – Research Report) yesterday and set a price target of $394.00. The ...

Lennar Corp Class A (LEN) stock saw a modest uptick, ending the day at $133.54 which represents a slight increase of $0.40 or 0.30% from the prior close of $133.14. The stock opened at $132.04 and ...

BTIG analyst Thomas Shrader lowered the firm’s price target on Denali Therapeutics (DNLI) to $32 from $35 and keeps a Buy rating on the shares after the company announced topline data from the Phase 2 ...

BTIG raised the firm’s price target on Glaukos (GKOS) to $157 from $149 and keeps a Buy rating on the shares as part of a broader research note updating the firm’s models on Medical Technology names ...

Carisma Therapeutics, Inc. (NASDAQ:CARM – Get Free Report) has earned an average recommendation of “Hold” from the seven ...